The Lancet Infectious Disease
Feb 2011  Volume 11 Number 2  Pages 73 – 152
http://www.thelancet.com/journals/laninf/issue/current

Comment
Immunological correlates of protection for the RTS,S candidate malaria vaccine
Brian Greenwood

Evidence continues to accumulate that the candidate malaria vaccine RTS,S provides substantial, although not complete, protection against malaria in African children. In The Lancet Infectious Diseases today, Olutu and colleagues1 add to this body of evidence, reporting persistence of protection for at least 15 months after vaccination of Kenyan and Tanzanian infants with the RTS,S candidate malaria vaccine formulated with the AS01 adjuvant. There was no evidence for a reduction in efficacy from that reported during the first 8 months of follow-up of this trial (around 50% efficacy).